Advanced Bitcoin Technologies AG Q3 FY2022 Earnings Call

· Earnings call transcript and AI-powered summary

Abbott Q3 2022 Earnings Summary

  • Earnings Per Share (EPS): Adjusted EPS of $1.15 for Q3 2022. Full-year adjusted EPS guidance raised to $5.17–$5.23 (up over 10% from initial January guidance).
  • Total Sales: Organic sales increased 1.3% year-over-year. Excluding COVID testing and nutrition disruption in the U.S., organic sales rose 6%.
  • COVID Testing Sales: $1.7 billion in Q3, down year-over-year due to reduced lab-based testing, but above expectations.
  • Impact of FX and Macro Headwinds: Foreign exchange reduced sales by 6% in Q3 with $0.10 EPS impact expected in Q4. Inflation and manufacturing/logistics costs continue to pressure margins.

Business Segment Performance

  • Established Pharmaceuticals (EPD): Sales grew 12% driven by India, China, Brazil, Vietnam. Double-digit growth continued since start of 2021.
  • Diagnostics: Rapid testing (e.g., BinaxNOW) held steady year-over-year; routine diagnostics grew 6% excluding COVID testing. Alinity platform expanded globally.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning, and thank you for standing by. Welcome to Abbott's Third Quarter 2022 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions. Scott Leinenweber: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer. Robert and Bob will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2022. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K the year ended December 31, 2021. Abbott

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional